Executive Summary: Key Takeaways

• Emerging Research: GLP-1 agonists, a class of drugs primarily used for type 2 diabetes and weight loss (e.g., Ozempic, Wegovy), are being investigated for their potential to lower the risk and slow the progression of Alzheimer’s disease.
• Promising Observational Data: Large-scale studies of patient data have shown that individuals with type 2 diabetes taking GLP-1 agonists have a significantly lower incidence of Alzheimer’s disease compared to those on other diabetes medications.
• Multiple Mechanisms of Action: These drugs may protect the brain by reducing neuroinflammation, improving insulin sensitivity, clearing harmful amyloid and tau proteins, and promoting neuron survival.
• Not a Current Treatment: GLP-1 agonists are not currently approved by the FDA for the prevention or treatment of Alzheimer’s disease. Their use for this purpose is still experimental.
• Ongoing Clinical Trials: Major clinical trials, such as the EVOKE and EVOKE+ trials for semaglutide, are underway to definitively determine the safety and efficacy of these drugs for Alzheimer’s.